{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:41:04Z","timestamp":1761100864198,"version":"build-2065373602"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,10,24]],"date-time":"2006-10-24T00:00:00Z","timestamp":1161648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Early prediction of response to therapy may offer the potential to identify patients who will benefit from standard conventional therapy. The objective of this study was to determine the predictive value of FDG\u2010PET as an early response indicator after 1 cycle of chemotherapy for progression\u2010free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>FDG\u2010PET was performed before, after 1 cycle, and after completion of chemotherapy in 47 patients. The patients were followed with a median follow\u2010up of 21 months (range, 3\u201347 months). PFS was compared between PET\u2010positive and PET\u2010negative patients after 1 cycle and after completion of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>All PET\u2010negative patients after 1 cycle (n = 31) had sustained complete remission with a median follow\u2010up of 28 months. Fourteen of 16 PET\u2010positive patients after 1 cycle had refractory disease or relapsed (median PFS, 5.5 months). There were 2 false\u2010positive results, 1 with an active infection at the biopsy site and the other in a patient who had been in remission after radiation therapy. There was good agreement between the results obtained after 1 cycle and at completion of therapy (kappa, 0.80); however, the negative predictive value was higher for FDG\u2010PET after 1 cycle than after completion of chemotherapy (100% vs 91.4%), although not statistically different (<jats:italic>P<\/jats:italic> = .40).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>FDG\u2010PET had a high prognostic value after 1 cycle of chemotherapy, thus it can be a valid alternative for posttreatment evaluation of DLCL and HD and may offer the potential for change in treatment paradigms. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22276","type":"journal-article","created":{"date-parts":[[2006,10,24]],"date-time":"2006-10-24T21:23:59Z","timestamp":1161725039000},"page":"2678-2687","source":"Crossref","is-referenced-by-count":141,"title":["FDG\u2010PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease"],"prefix":"10.1002","volume":"107","author":[{"given":"Lale","family":"Kostakoglu","sequence":"first","affiliation":[]},{"given":"Stanley J.","family":"Goldsmith","sequence":"additional","affiliation":[]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[]},{"given":"Tamer","family":"Atasever","sequence":"additional","affiliation":[]},{"given":"Angely","family":"Chandramouly","sequence":"additional","affiliation":[]},{"given":"Sumeet","family":"Verma","sequence":"additional","affiliation":[]},{"given":"Pratichi","family":"Kothari","sequence":"additional","affiliation":[]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2006,10,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22178"},{"volume-title":"Hodgkin's disease","year":"1999","author":"Mauch PM","key":"e_1_2_5_3_2"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390104"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-68"},{"key":"e_1_2_5_8_2","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu L","year":"2002","journal-title":"J Nucl Med."},{"key":"e_1_2_5_9_2","first-page":"613","article-title":"Persistent tumor 18F\u2010FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non\u2010 Hodgkin's lymphoma","volume":"85","author":"Jerusalem G","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf256"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi272"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0272"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2252"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.414"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008357126404"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03147.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2930"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1623988"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602040"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.891"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1375-y"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.2.160"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_2.177"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.1074"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/13.S1.86"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10391"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22276","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:04:22Z","timestamp":1760295862000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,24]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1002\/cncr.22276"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22276","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2006,10,24]]}}}